LYPD4 and neoplasm: Consistent with this observation and our previous report(5), lapatinib treatment dramatically enhanced alectinib responses in H3122 xenografts, inducing stronger tumor regression compared to the enhancement of individual SMR mechanisms (Fig. 6C and Fig. S10A).